PR Newswire Clinical TrialsOriginal article
Nixodine-S™ Study Signals a Potential Breakthrough Beyond Nicotine
Data ReadoutpositiveNixodine-S™Positive
AI Analysis
Summary
Bonguard Naturals announced positive results for Nixodine-S™, a patented nicotine alternative that maintained satisfaction-related receptor activity while demonstrating improved in vitro cytotoxicity profile compared to nicotine.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Patented alternative preserved nicotine-like activity at key satisfaction-related receptors while producing markedly more favorable in vitro cytotoxicity result than nicotine
Importance:5/10
Sentiment:
0.70
nicotine alternativecytotoxicityreceptor activitysafety profile
Read the original article
Published by PR Newswire Clinical Trials on August 24, 2026 5:53 PM